MD Anderson, P-Cure Ally on Helium Ion Therapy
The partnership aims to develop a compact platform combining proton and helium ion therapy for cancer treatment.
Updated on Nov. 9, 2026 in Healthcare
The University of Texas MD Anderson Cancer Center and P-Cure Ltd. announced a strategic alliance on November 8, 2026, to develop a compact upright platform delivering both proton and helium ion therapy. UT MD Anderson is eligible to receive payments tied to clinical milestones and commercial sales.
Why it matters
Helium ions are emerging as a next-generation modality that may offer improved dose conformity and enhanced biological effectiveness. The collaboration seeks to determine how these characteristics can be translated into improved patient outcomes in Houston and beyond.
The alliance was announced on November 8, 2026, and would be the first helium particle system in North America if successfully developed. Payment amounts and specific clinical milestones tied to MD Anderson's eligibility were not disclosed.
The players
University of Texas MD Anderson Cancer Center
A major cancer treatment and research institution in Houston, Texas, widely recognized for its oncology programs.
P-Cure Ltd.
A company developing compact upright particle therapy systems, including an FDA-cleared proton therapy platform.
The details
The collaboration will include clinical evaluation of P-Cure's FDA-cleared proton therapy platform alongside preclinical studies of the biological advantages of helium ions. Initial work will focus on the clinical value, patient benefits, and operational advantages of P-Cure's compact upright proton therapy solution.
Timeline
November 8, 2026: MD Anderson and P-Cure announce the strategic alliance.
Market Landscape
The alliance builds on FDA-cleared proton therapy by pursuing helium ions, a modality that has not yet been widely deployed. It positions MD Anderson and P-Cure in a competitive area of particle radiation therapy where compact, upright systems are a growing focus.
For patients, the alliance could eventually expand access to particle therapy options if the compact platform and helium ion treatments prove clinically useful. Any changes to availability or cost would depend on the outcome of the planned clinical and regulatory work.
The takeaway
Patients considering advanced radiation options should ask their oncology teams about proton and emerging particle therapies available at their treatment center. Developments like this remain in early stages until clinical results are published.
Further reading
Explore more in Healthcare coverage from Houston.
Source note: This article includes information reported by News-Medical.
